

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1653HXP

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 FEB 27 New STN AnaVist pricing effective March 1, 2006
NEWS 4 APR 04 STN AnaVist \$500 visualization usage credit offered
NEWS 5 MAY 10 CA/Caplus enhanced with 1900-1906 U.S. patent records
NEWS 6 MAY 11 KOREAPAT updates resume
NEWS 7 MAY 19 Derwent World Patents Index to be reloaded and enhanced
NEWS 8 MAY 30 IPC 8 Rolled-up Core codes added to CA/Caplus and
USPATFULL/USPAT2
NEWS 9 MAY 30 The F-Term thesaurus is now available in CA/Caplus
NEWS 10 JUN 02 The first reclassification of IPC codes now complete in
INPADOC
NEWS 11 JUN 26 TULSA/TULSA2 reloaded and enhanced with new search and
and display fields
NEWS 12 JUN 28 Price changes in full-text patent databases EPFULL and PCTFULL
NEWS 13 JUL 07 Coverage of Research Disclosure reinstated in DWPI

NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:23:43 ON 10 JUL 2006

=> file medline, uspatful, biosis, wpids

COST IN U.S. DOLLARS

SINCE FILE
ENTRY

TOTAL
SESSION

FULL ESTIMATED COST

2.10

2.10

FILE 'MEDLINE' ENTERED AT 13:29:53 ON 10 JUL 2006

FILE 'USPATFULL' ENTERED AT 13:29:53 ON 10 JUL 2006

CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 13:29:53 ON 10 JUL 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'WPIDS' ENTERED AT 13:29:53 ON 10 JUL 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

=> s alpha-2 antiplasmin
L1 3327 ALPHA-2 ANTIPLASMIN

=> s l1 and cleaving enzyme
L2 7 L1 AND CLEAVING ENZYME

=> d l2 ti abs ibib tot

L2 ANSWER 1 OF 7 USPATFULL on STN
TI Methods and diagnosis for the treatment of preeclampsia
AB Provided by the present invention are methods for treating and
diagnosing preeclampsia, as well as kits for use in diagnosing patients
with a higher risk of preeclampsia.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:292568 USPATFULL
TITLE: Methods and diagnosis for the treatment of preeclampsia
INVENTOR(S): Labat, Ivan, Mountain View, CA, UNITED STATES
Tang, Y. Tom, San Jose, CA, UNITED STATES
Stache-Crain, Birgit, Sunnyvale, CA, UNITED STATES
Boyle, Bryan, Palo Cedro, CA, UNITED STATES
PATENT ASSIGNEE(S): NUVELO, Inc., Sunnyvale, CA, UNITED STATES (U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005255114	A1	20051117
APPLICATION INFO.:	US 2004-821234	A1	20040407 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-462047P	20030407 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	NUVELO, INC, 675 ALMANOR AVE., SUNNYVALE, CA, 94085, US	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
LINE COUNT:	28980	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 2 OF 7 USPATFULL on STN
TI Assay methods for detecting serum proteases, particularly activated
protein C
AB The invention describes diagnostic methods and compositions for
determining the amount of protease in a body fluid sample. In
particular, the invention detects proteases by a method in which both a
reversible inhibitor of the protease and an irreversible inhibitor of
interfering proteases during the detection step are employed to increase
the sensitivity of the enzyme capture assay. The assay detects normal
serum levels of activated protein C.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 94:15636 USPATFULL
TITLE: Assay methods for detecting serum proteases,
particularly activated protein C

INVENTOR(S): Griffin, John H., Del Mar, CA, United States
Gruber, Andras, San Diego, CA, United States
PATENT ASSIGNEE(S): The Scripps Research Institute, La Jolla, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5288612		19940222
APPLICATION INFO.:	US 1991-725359		19910703 (7)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Griffin, Ronald W.		
ASSISTANT EXAMINER:	Webber, Pamela S.		
LEGAL REPRESENTATIVE:	Bingham, Douglas A., Fitting, Thomas, Logan, April C.		
NUMBER OF CLAIMS:	9		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 3 Drawing Page(s)		
LINE COUNT:	1792		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

L2 ANSWER 3 OF 7 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI Antiplasmin-cleaving enzyme is a soluble form of
fibroblast activation protein.
AB Circulating antiplasmin-cleaving enzyme (APCE) has a
role in fibrinolysis and appears structurally similar to fibroblast
activation protein (FAP), a cell-surface proteinase that promotes
invasiveness of certain epithelial cancers. To explore this potential
relationship, we performed comparative structure/function analyses of the
2 enzymes. APCE from human plasma and recombinant FAP (rFAP) exhibited
identical pH optima of 7.5, extinction coefficients (is an element
of(1%)(280nm)) of 20.2 and 20.5, common sequences of tryptic peptides, and
crossreactivity with FAP antibody. APCE and rFAP are homodimers with
monomeric subunits of 97 and 93 kDa. Only homodimers appear to have
enzymatic activity, with essentially identical kinetics toward Met-
alpha(2)-antiplasmin (Met-alpha(2)AP) and
peptide substrates. APCE and rFAP cleave both Pro3-Leu4 and Pro12-Asn13
bonds of Met-alpha(2)AP, but relative k(cat)/K-m values for Pro12-Asn13
are about 16-fold higher than for Pro3-Leu4. APCE and rFAP demonstrate
higher k(cat)/K-m values toward a peptide modeled on P4-P4' sequence
surrounding the Pro12-Asn13 primary cleavage site than for Z-Gly-Pro-AMC
and Ala-Pro-AFC substrates. These data support APCE as a soluble
derivative of FAP and Met-alpha(2)AP as its physiologic substrate.
Conversion of Met-alpha(2)AP by membrane or soluble FAP to the more easily
fibrin-incorporable form, Asn-alpha(2)AP, may increase plasmin inhibition
within fibrin surrounding certain neoplasms and have an impact on growth
and therapeutic susceptibility.

ACCESSION NUMBER: 2006:290408 BIOSIS

DOCUMENT NUMBER: PREV200600289808

TITLE: Antiplasmin-cleaving enzyme is a
soluble form of fibroblast activation protein.

AUTHOR(S): Lee, Kyung N. [Reprint Author]; Jackson, Kenneth W.;
Christiansen, Victoria J.; Lee, Chung S.; Chun, Jin-Geun;
McKee, Patrick A.

CORPORATE SOURCE: Univ Oklahoma, Hlth Sci Ctr, WK Warren Med Res Ctr, POB
26901, BSEB 306, Oklahoma City, OK 73190 USA
kyung-lee@ouhsc.edu

SOURCE: Blood, (FEB 15 2006) Vol. 107, No. 4, pp. 1397-1404.
CODEN: BLOOAW. ISSN: 0006-4971.

DOCUMENT TYPE: Article

LANGUAGE: English

ENTRY DATE: Entered STN: 31 May 2006

Last Updated on STN: 31 May 2006

L2 ANSWER 4 OF 7 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
 TI Determination of antiplasmin cleaving enzyme substrate
 specificity and inhibitor development by peptide library analyzes.
 AB Plasma alpha(2)-antiplasmin (Met-alpha(2)AP)
 is slowly cleaved in the circulation by antiplasmin cleaving
 enzyme (APCE) to form Asn-alpha(2)AP, which crosslinks to fibrin
 similar to 13-fold faster than Met-a2AP. Blood clots generated in the
 presence of Asn-alpha(2)AP are moreresistant to fibrinolysis than those
 formed in the presence of Met-a2AP. Inhibition of plasma APCE may result
 in clots that are more easily removed during fibrinolysis. Therefore an
 inhibitor specific for APCE might be useful in the regulation of
 fibrinolysis. We previously reported Met-alpha(2)AP is cleaved at
 Prol2-Asn13 to produce Asn-a2AP, but little more is known about substrate
 specificity other than the apparent Pro specificity in the P, position. To
 delineate APCE substrate specificity we synthesized peptide libraries
 derived from the P4-P4(1) amino acid sequence of Met-alpha(2)AP. There were
 152 peptides consisting of the 19 common amino acids except Cys, which
 were varied in the eight positions. Each peptide differed by one amino
 acid. Each peptide in these libraries was then assayed for relative
 K-cat/K-m values compared to the corresponding native peptide. As
 expected, position P-1 required Pro. Only Gly was acceptable in P-2; P-2'
 had a preference for Trp; and none of the eight positions tolerated Lys or
 Arg. Based on optimized sequences, first generation inhibitors were
 synthesized and tested.

ACCESSION NUMBER: 2005:532236 BIOSIS
 DOCUMENT NUMBER: PREV200510325751
 TITLE: Determination of antiplasmin cleaving
 enzyme substrate specificity and inhibitor
 development by peptide library analyzes.
 AUTHOR(S): Jackson, Kenneth W. [Reprint Author]; Christiansen,
 Victoria J.; Lee, Kyung N.; McKee, Patrick A.
 CORPORATE SOURCE: Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK
 73104 USA
 SOURCE: FASEB Journal, (MAR 4 2005) Vol. 19, No. 4, Suppl. S, Part
 1, pp. A864.
 Meeting Info.: Experimental Biology 2005 Meeting/35th
 International Congress of Physiological Sciences. San
 Diego, CA, USA. March 31 -April 06, 2005. Amer Assoc
 Anatomists; Amer Assoc Immunologists; Amer Physiol Soc;
 Amer Soc Biochem & Mol Biol; Amer Soc Investigat Pathol;
 Amer Soc Nutr Sci; Amer Soc Pharmacol & Expt Therapeut; Int
 Union Physiol Sci.
 CODEN: FAJOEC. ISSN: 0892-6638.
 DOCUMENT TYPE: Conference; (Meeting)
 Conference; Abstract; (Meeting Abstract)
 LANGUAGE: English
 ENTRY DATE: Entered STN: 1 Dec 2005
 Last Updated on STN: 1 Dec 2005

L2 ANSWER 5 OF 7 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
 TI Plasma antiplasmin-cleaving enzyme (APCE) is a soluble
 form of fibroblast activation protein (FAP).
 AB We recently reported that a novel human plasma proteinase, APCE, has a
 role infibrin digestion. Because APCE possesses similarities in sequence
 to FAP, which appears to contribute to the invasiveness of
 epithelial-derived cancers, wecompared properties of the two enzymes,
 hypothesizing that APCE is a soluble derivative of FAP. Recombinant
 soluble human FAP containing amino acid residues 35 to 760 was produced in
 Pichia pastoris and APCE was purified from human plasma. Both
 cross-reacted with antibody to FAP, existed as dimers; under native
 conditions, and had virtually identical molecular weights and subunit
 structures: rFAP 173 kDa, monomer 94 kDa; APCE 179 kDa, monomer 97 kDa.
 Both exhibited pH optima of 7.5 and essentially identical kinetic

parameters towards synthetic substrates. While no biologic substrate is known for membrane-bound FAP, we found that rFAP cleaved the Pro 12-Asn 13 bond of human alpha(2)-antiplasmin, which we have shown is a physiologic substrate of APCE. N-terminal and partial tryptic peptide sequences of APCE were identical to similar to 50% of FAP primary structure. The homodimeric forms of rFAP or APCE cleaved gelatin on zymography, whereas monomers of either had no activity. These data support the hypothesis that APCE is a soluble derivative of FAP and suggest that specific inhibitor development for FAP or APCE might be approached using alpha(2)-antiplasmin as a template.

ACCESSION NUMBER: 2005:529631 BIOSIS
DOCUMENT NUMBER: PREV200510323146
TITLE: Plasma antiplasmin-cleaving enzyme (APCE) is a soluble form of fibroblast activation protein (FAP).
AUTHOR(S): Lee, K. N. [Reprint Author]; Jackson, K. W.; Christiansen, V. J.; McKee, P. A.
CORPORATE SOURCE: Univ Oklahoma, Hlth Sci Ctr, Warren Med Res Ctr, Oklahoma City, OK 73104 USA
SOURCE: FASEB Journal, (MAR 4 2005) Vol. 19, No. 4, Suppl. S, Part 1, pp. A304-A305.
Meeting Info.: Experimental Biology 2005 Meeting/35th International Congress of Physiological Sciences. San Diego, CA, USA. March 31 -April 06, 2005. Amer Assoc Anatomists; Amer Assoc Immunologists; Amer Physiol Soc; Amer Soc Biochem & Mol Biol; Amer Soc Investigat Pathol; Amer Soc Nutr Sci; Amer Soc Pharmacol & Expt Therapeut; Int Union Physiol Sci.
CODEN: FAJOEC. ISSN: 0892-6638.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 1 Dec 2005
Last Updated on STN: 1 Dec 2005

L2 ANSWER 6 OF 7 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI A novel plasma proteinase potentiates alpha2-antiplasmin inhibition of fibrin digestion.
AB Human alpha2-antiplasmin (alpha2AP), also known as alpha2-plasmin inhibitor, is the major inhibitor of the proteolytic enzyme plasmin that digests fibrin. There are 2 N-terminal forms of alpha2AP that circulate in human plasma: a 464-residue protein with Met as the N-terminus, Met-alpha2AP, and a 452-residue version with Asn as the N-terminus, Asn-alpha2AP. We have discovered and purified a proteinase from human plasma that cleaves the Prol2-Asn13 bond of Met-alpha2AP to yield Asn-alpha2AP and have named it antiplasmin-cleaving enzyme (APCE). APCE is similar in primary structure and catalytic properties to membranebound fibroblast activation protein/seprase for which a physiologic substrate has not been clearly defined. We found that Asn-alpha2AP becomes cross-linked to fibrin by activated factor XIII approximately 13 times faster than native Met alpha2AP during clot formation and that clot lysis rates are slowed in direct proportion to the ratio of Asn-alpha2AP to Met-alpha2AP in human plasma. We conclude that APCE cleaves Met-alpha2AP to the derivative Asn- CLAP, which is more efficiently incorporated into fibrin and consequently makes it strikingly resistant to plasmin digestion. APCE may represent a new target for pharmacologic inhibition, since less generation and incorporation of Asn-alpha2AP could result in a more rapid removal of fibrin by plasmin during atherogenesis, thrombosis, and inflammatory states. Copyright 2004 by The American Society of Hematology.

ACCESSION NUMBER: 2004:390324 BIOSIS
DOCUMENT NUMBER: PREV200400388355

TITLE: A novel plasma proteinase potentiates alpha2-antiplasmin inhibition of fibrin digestion.
AUTHOR(S): Lee, Kyung N.; Jackson, Kenneth W.; Christiansen, Victoria J.; Chung, Keun H.; McKee, Patrick A. [Reprint Author]
CORPORATE SOURCE: Hlth Sci CtrWilliam K Warren Med Res Ctr, Univ Oklahoma, POB 26901,BSEB-306, Oklahoma City, OK, 73190, USA
patrick-mckee@ouhsc.edu
SOURCE: Blood, (May 15 2004) Vol. 103, No. 10, pp. 3783-3788.
print.
CODEN: BLOOAW. ISSN: 0006-4971.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 6 Oct 2004
Last Updated on STN: 6 Oct 2004

L2 ANSWER 7 OF 7 WPIDS COPYRIGHT 2006 THE THOMSON CORP on STN

TI New alpha-2-antiplasmin cleaving enzyme, useful for treating conditions involving fibrin, e.g. inflammatory conditions such all forms of arthritis, organ fibrosis, undesirable scarring, cancer, or atherothrombotic disease.
AN 2004-625848 [60] WPIDS
AB WO2004072240 A UPAB: 20040920
NOVELTY - An alpha 2-antiplasmin cleaving enzyme comprising a protein having a molecular weight of 180 kDa in a dimeric form as determined by SDS-PAGE, where each subunit of the dimeric form has a molecular weight of 97 kDa as determined by SDS-PAGE, and where the enzyme cleaves precursor alpha 2-antiplasmin at the prol2-asn13 bond of alpha 2-antiplasmin, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:

- (1) a method of screening for inhibitors of antiplasmin cleaving enzyme;
- (2) an inhibitor of alpha2-antiplasmin cleaving enzyme identified by the screening method;
- (3) an inhibitor of antiplasmin cleaving enzyme that is effective in binding to or blocking the alpha2-antiplasmin binding site of alpha2-antiplasmin prol2-asn13 cleaving site of the antiplasmin cleaving enzyme;
- (4) a method for identifying an enzyme inhibitor;
- (5) an antibody raised against alpha2-antiplasmin cleaving enzyme, which binds to an alpha2-antiplasmin binding portion of the alpha2-antiplasmin cleaving enzyme;
- (6) a method of screening a subject at risk for atherosclerosis or its complications, or for diseases related to fibrin deposition;
- (7) methods of inhibiting digestion by plasmin in a subject in need of such therapy;
- (8) method of producing activated alpha2-antiplasmin, in vitro; and
- (9) a method of enhancing fibrin digestion in vivo.

ACTIVITY - Antiinflammatory; Cytostatic; Vulnerary; Antiarteriosclerotic; Antithrombotic; Vascular-Gen; Cerebroprotective; Pulmonary-Gen. No biological data given.

MECHANISM OF ACTION - Alpha-2-antiplasmin -inhibitor.

USE - The enzyme, inhibitors and methods are useful for treating conditions involving fibrin, e.g. inflammatory conditions such as all forms of arthritis, organ fibrosis, undesirable scarring, cancer or its metastases; or atherothrombotic disease such as coronary artery thrombosis, stroke, pulmonary embolism, all other forms of arterial and venous thromboses.

Dwg.0/4

ACCESSION NUMBER: 2004-625848 [60] WPIDS
DOC. NO. CPI: C2004-225158

TITLE: New alpha-2-antiplasmin
 cleaving enzyme, useful for treating
 conditions involving fibrin, e.g. inflammatory conditions
 such all forms of arthritis, organ fibrosis, undesirable
 scarring, cancer, or atherothrombotic disease.
 DERWENT CLASS: B04 D16
 INVENTOR(S): CHRISTIANSEN, V J; JACKSON, K W; LEE, K N; MCKEE, P A
 PATENT ASSIGNEE(S): (CHRI-I) CHRISTIANSEN V J; (JACK-I) JACKSON K W; (LEEK-I)
 LEE K N; (MCKE-I) MCKEE P A
 COUNTRY COUNT: 109
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2004072240	A2	20040826	(200460)*	EN	40
RW: AT BE BG BW CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE					
LS LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE					
DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG					
KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ					
OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG					
US UZ VC VN YU ZA ZM ZW					
US 2004203102	A1	20041014	(200468)		
EP 1597360	A2	20051123	(200577)	EN	
R: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LT LU LV					
MC MK NL PT RO SE SI SK TR					

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2004072240	A2	WO 2004-US3398	20040207
US 2004203102	A1 Provisional	US 2003-445774P	20030207
		US 2004-774242	20040206
EP 1597360	A2	EP 2004-709157	20040207
		WO 2004-US3398	20040207

FILING DETAILS:

PATENT NO	KIND	PATENT NO
EP 1597360	A2 Based on	WO 2004072240

PRIORITY APPLN. INFO: US 2004-774242 20040206; US
 2003-445774P 20030207

=> d his

(FILE 'HOME' ENTERED AT 13:23:43 ON 10 JUL 2006)

FILE 'MEDLINE, USPATFULL, BIOSIS, WPIDS' ENTERED AT 13:29:53 ON 10 JUL 2006

L1 3327 S ALPHA-2 ANTIPLASMIN
 L2 7 S L1 AND CLEAVING ENZYME

=> s alpha-2-antiplasmin cleaving enzyme and (pro12-asn13 bond)
 L3 1 ALPHA-2-ANTIPLASMIN CLEAVING ENZYME AND (PRO12-ASN13 BOND)

=> d l3 ti abs ibib tot

L3 ANSWER 1 OF 1 WPIDS COPYRIGHT 2006 THE THOMSON CORP on STN
 TI New alpha-2-antiplasmin cleaving

enzyme, useful for treating conditions involving fibrin, e.g. inflammatory conditions such all forms of arthritis, organ fibrosis, undesirable scarring, cancer, or atherothrombotic disease.

AN 2004-625848 [60] WPIDS

AB WO2004072240 A UPAB: 20040920

NOVELTY - An alpha 2-antiplasmin

cleaving enzyme comprising a protein having a molecular weight of 180 kDa in a dimeric form as determined by SDS-PAGE, where each subunit of the dimeric form has a molecular weight of 97 kDa as determined by SDS-PAGE, and where the enzyme cleaves precursor alpha 2-antiplasmin at the pro12-asn13 bond of alpha 2-antiplasmin, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:

(1) a method of screening for inhibitors of antiplasmin cleaving enzyme;

(2) an inhibitor of alpha2-antiplasmin cleaving enzyme identified by the screening method;

(3) an inhibitor of antiplasmin cleaving enzyme that is effective in binding to or blocking the alpha2-antiplasmin binding site of alpha2-antiplasmin pro12-asn13 cleaving site of the antiplasmin cleaving enzyme;

(4) a method for identifying an enzyme inhibitor;

(5) an antibody raised against alpha2-antiplasmin cleaving enzyme, which binds to an alpha2-antiplasmin binding portion of the alpha2-antiplasmin cleaving enzyme;

(6) a method of screening a subject at risk for atherosclerosis or its complications, or for diseases related to fibrin deposition;

(7) methods of inhibiting digestion by plasmin in a subject in need of such therapy;

(8) method of producing activated alpha2-antiplasmin, in vitro; and

(9) a method of enhancing fibrin digestion in vivo.

ACTIVITY - Antiinflammatory; Cytostatic; Vulnerary; Antiarteriosclerotic; Antithrombotic; Vascular-Gen; Cerebroprotective; Pulmonary-Gen. No biological data given.

MECHANISM OF ACTION - Alpha-2-antiplasmin-inhibitor.

USE - The enzyme, inhibitors and methods are useful for treating conditions involving fibrin, e.g. inflammatory conditions such as all forms of arthritis, organ fibrosis, undesirable scarring, cancer or its metastases; or atherothrombotic disease such as coronary artery thrombosis, stroke, pulmonary embolism, all other forms of arterial and venous thromboses.

Dwg.0/4

ACCESSION NUMBER: 2004-625848 [60] WPIDS

DOC. NO. CPI: C2004-225158

TITLE: New alpha-2-antiplasmin cleaving enzyme, useful for treating conditions involving fibrin, e.g. inflammatory conditions such all forms of arthritis, organ fibrosis, undesirable scarring, cancer, or atherothrombotic disease.

DERWENT CLASS: B04 D16

INVENTOR(S): CHRISTIANSEN, V J; JACKSON, K W; LEE, K N; MCKEE, P A

PATENT ASSIGNEE(S): (CHRI-I) CHRISTIANSEN V J; (JACK-I) JACKSON K W; (LEEK-I) LEE K N; (MCKE-I) MCKEE P A

COUNTRY COUNT: 109

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2004072240	A2	20040826	(200460)*	EN	40
RW: AT BE BG BW CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE					
LS LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE					

DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG
 KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ
 OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG
 US UZ VC VN YU ZA ZM ZW
 US 2004203102 A1 20041014 (200468)
 EP 1597360 A2 20051123 (200577) EN
 R: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LT LU LV
 MC MK NL PT RO SE SI SK TR

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2004072240	A2	WO 2004-US3398	20040207
US 2004203102	A1 Provisional	US 2003-445774P	20030207
		US 2004-774242	20040206
EP 1597360	A2	EP 2004-709157	20040207
		WO 2004-US3398	20040207

FILING DETAILS:

PATENT NO	KIND	PATENT NO
EP 1597360	A2 Based on	WO 2004072240

PRIORITY APPLN. INFO: US 2004-774242 20040206; US
 2003-445774P 20030207

Refine Search

Search Results -

Terms	Documents
L12 and l15	0

Database:

US Pre-Grant Publication Full-Text Database

US Patents Full-Text Database

US OCR Full-Text Database

EPO Abstracts Database

JPO Abstracts Database

Derwent World Patents Index

IBM Technical Disclosure Bulletins

Search:

L13

Refine Search

Recall Text

Clear

Interrupt

Search History

DATE: Monday, July 10, 2006 [Printable Copy](#) [Create Case](#)

Set Name **Query**

side by side

Hit Count

Set Name

result set

DB=USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR

<u>L13</u>	L12 and l15	0	<u>L13</u>
<u>L12</u>	L10 and (pro12-asn13 bond)	58	<u>L12</u>
<u>L11</u>	L10 (precursor alpha-2-antiplasmin)	208235	<u>L11</u>
<u>L10</u>	L9 and (enzyme)	72	<u>L10</u>
<u>L9</u>	L8 and (cleavage)	73	<u>L9</u>

DB=USPT; PLUR=YES; OP=OR

<u>L8</u>	L6 and (dimeric form)	109	<u>L8</u>
<u>L7</u>	L6 and l5	0	<u>L7</u>
<u>L6</u>	alpha-2-antiplasmin	111	<u>L6</u>
<u>L5</u>	mckee.in.	1481	<u>L5</u>
<u>L4</u>	6455677.pn.	1	<u>L4</u>
<u>L3</u>	5965373.pn.	1	<u>L3</u>
<u>L2</u>	5587299.pn.	1	<u>L2</u>
<u>L1</u>	5587299.pn.	1	<u>L1</u>

END OF SEARCH HISTORY

Hit List

[Clear](#) [Generate Collection](#) [Print](#) [Fwd Refs](#) [Bkwd Refs](#) [Generate OACS](#)

Search Results - Record(s) 1 through 10 of 58 returned.

☐ 1. Document ID: US 7041287 B2

L12: Entry 1 of 58

File: USPT

May 9, 2006

US-PAT-NO: 7041287
DOCUMENT-IDENTIFIER: US 7041287 B2

TITLE: Compositions and methods for selective dissolution of nascent intravascular blood clots

DATE-ISSUED: May 9, 2006

PRIOR-PUBLICATION:

DOC-ID	DATE
US 20040053408 A1	March 18, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Muzykantov; Vladimir R.	Warwick	PA		US
Murciano; Juan Carlos	Sevilla			ES
Cines; Douglas	Wynnewood	PA		US

US-CL-CURRENT: 424/94.3; 435/188, 436/519, 514/2

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	-----------	-----

☐ 2. Document ID: US 7037911 B2

L12: Entry 2 of 58

File: USPT

May 2, 2006

US-PAT-NO: 7037911
DOCUMENT-IDENTIFIER: US 7037911 B2

TITLE: Amino-bicyclic pyrazinones and pyridinones as coagulation serine protease inhibitors

DATE-ISSUED: May 2, 2006

PRIOR-PUBLICATION:

DOC-ID	DATE
US 20050038030 A1	February 17, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Zhang; Xiaojun	Hockessin	DE		US

US-CL-CURRENT: 514/249; 544/349

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	-----------	-----

☐ 3. Document ID: US 7037667 B1

L12: Entry 3 of 58

File: USPT

May 2, 2006

US-PAT-NO: 7037667

DOCUMENT-IDENTIFIER: US 7037667 B1

TITLE: Tumor antigen useful in diagnosis and therapy of prostate and colon cancer

DATE-ISSUED: May 2, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Afar; Daniel E. H.	Pacific Palisades	CA		US
Hubert; Rene S.	Los Angeles	CA		US
Leong; Kahan	Playa Del Rey	CA		US
Raitano; Arthur B.	Los Angeles	CA		US
Saffran; Douglas	Los Angeles	CA		US
Mitchell; Stephen C.	Santa Monica	CA		US
Jakobovits; Aya	Beverly Hills	CA		US
Faris; Mary	Los Angeles	CA		US
Vivanco; Igor	Los Angeles	CA		US

US-CL-CURRENT: 435/7.23; 435/6, 436/64

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-----------	-----

☐ 4. Document ID: US 7030289 B2

L12: Entry 4 of 58

File: USPT

Apr 18, 2006

US-PAT-NO: 7030289

DOCUMENT-IDENTIFIER: US 7030289 B2

TITLE: Stabilization of milk from transgenic animals

DATE-ISSUED: April 18, 2006

PRIOR-PUBLICATION:

DOC-ID	DATE
US 20030088881 A1	May 8, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cottingham; Ian Robert	Midlothian			GB
McCreath; Graham Edward	Edinburgh			GB

US-CL-CURRENT: 800/7; 435/69.1, 800/14, 800/15, 800/16, 800/17, 800/18, 800/25

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-----------	-----

☐ 5. Document ID: US 7026282 B1

L12: Entry 5 of 58

File: USPT

Apr 11, 2006

US-PAT-NO: 7026282
DOCUMENT-IDENTIFIER: US 7026282 B1

TITLE: Peptide antagonists of the human urokinase receptor and method for selecting them

DATE-ISSUED: April 11, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ploug; Michael	Copenhagen			DK
Ostergaard; So	Copenhagen			DK
Holst-Hansen; Claus	Frederiksberg			DK
Stephens; Ross	Charlottenlund			DK
Dano; Keld	Charlottenlund			DK
Holm; Arne	Holte			DK

US-CL-CURRENT: 514/2; 514/15, 530/328, 530/350

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	WMO	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	-----------	-----

6. Document ID: US 7005500 B2

L12: Entry 6 of 58

File: USPT

Feb 28, 2006

US-PAT-NO: 7005500
DOCUMENT-IDENTIFIER: US 7005500 B2

TITLE: Human cDNAs and proteins and uses thereof

DATE-ISSUED: February 28, 2006

PRIOR-PUBLICATION:

DOC-ID	DATE
US 20030096247 A1	May 22, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bejanin; Stephane	Paris			FR
Tanaka; Hiroaki	Antony			FR

US-CL-CURRENT: 530/350

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	WMO	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	-----------	-----

7. Document ID: US 6989262 B2

L12: Entry 7 of 58

File: USPT

Jan 24, 2006

US-PAT-NO: 6989262
DOCUMENT-IDENTIFIER: US 6989262 B2

TITLE: Plasmin variants and uses thereof

DATE-ISSUED: January 24, 2006

PRIOR-PUBLICATION:

DOC-ID
US 20030157485 A1

DATE
August 21, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bejanin; Stephane	Paris			FR
Tanaka; Hiroaki	Antony			FR

US-CL-CURRENT: 435/226; 424/94.64, 435/252.3, 435/41, 435/68.1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	RMK	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	-----------	-----

☐ 8. Document ID: US 6969515 B2

L12: Entry 8 of 58

File: USPT

Nov 29, 2005

US-PAT-NO: 6969515
DOCUMENT-IDENTIFIER: US 6969515 B2

TITLE: Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin

DATE-ISSUED: November 29, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Jesmok; Gary J.	Raleigh	NC		
Landskroner; Kyle A.	Raleigh	NC		

US-CL-CURRENT: 424/94.64

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	RMK	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	-----------	-----

☐ 9. Document ID: US 6964764 B2

L12: Entry 9 of 58

File: USPT

Nov 15, 2005

US-PAT-NO: 6964764
DOCUMENT-IDENTIFIER: US 6964764 B2

TITLE: Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin

DATE-ISSUED: November 15, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Zimmerman; Thomas P.	Raleigh	NC		
Novokhatny; Valery	Raleigh	NC		
Landskroner; Kyle A.	Mill Valley	CA		
Jesmok; Gary J.	Richmond	CA		
Taylor; Kathryn K.	Apex	NC		

US-CL-CURRENT: 424/94.64; 435/215, 435/217

☐ 10. Document ID: US 6951717 B1

L12: Entry 10 of 58

File: USPT

Oct 4, 2005

US-PAT-NO: 6951717

DOCUMENT-IDENTIFIER: US 6951717 B1

TITLE: Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission

DATE-ISSUED: October 4, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Barney; Shawn O'Lin	Cary	NC		
Lambert; Dennis Michael	Cary	NC		
Petteway; Stephen Robert	Cary	NC		

US-CL-CURRENT: 435/5; 424/211.1, 530/300

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
L10 and (pro12-asn13 bond)	58

Display Format:

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)